Plant Name: Glycyrrhiza inflata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| ADRA2C; ADRA2A; GPBAR1; | |
| ALPI; PLA2G1B; TDP1; BLM; P4HB; HPGD; HSD11B1; HSD11B2; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; AKR1B10; USP2; BRCA1; TNKS; PARP1; TNKS2; APEX1; POLB; CES2; AOX1; | |
| MGAM; ACHE; GAA; | |
| PTPN1; CDC25B; PTPN11; PTPN2; | |
| PDE5A; | |
| ABL1; MAPK1; EGFR; ATM; PTK2B; | |
| CA14; CA5B; CA3; CA1; CA12; CA9; CA7; CA4; CA6; CA2; CA5A; | |
| NR1H4; | |
| ESRRB; ESRRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; TYR; XDH; | |
| CASP7; CASP1; | |
| HIF1A; NFKB1; TP53; | |
| KMT2A; | |
| ABCC1; ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; MCL1; MAPT; HBB; THPO; HTT; RAB9A; NPC1; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
| Protein Kinase | PTK2B | Protein tyrosine kinase 2 beta | Q14289 | CHEMBL5469 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.877E-13 | 6.735E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.334E-12 | 1.970E-09 | ALPI, BLM, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, KMT2A, NR1H4, PARP1, PTPN1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.241E-11 | 8.719E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.671E-11 | 2.749E-08 | ABL1, ATM, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PLA2G1B, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.606E-10 | 1.234E-07 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1, NPC1, NR1H4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.670E-10 | 2.034E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.136E-10 | 2.193E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.661E-10 | 2.737E-07 | ABL1, ADRA2A, ATM, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PARP1, PLA2G1B, PTK2B, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.754E-10 | 3.404E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.760E-08 | 4.528E-06 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.981E-08 | 9.031E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 9.356E-08 | 1.852E-05 | ABL1, APEX1, BLM, BRCA1, CASP7, CYP1A1, CYP1B1, EGFR, ESR1, MAPK1, NFKB1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.217E-07 | 3.989E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.217E-07 | 3.989E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.032E-07 | 6.703E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 8.009E-07 | 1.220E-04 | ABL1, ATM, BRCA1, MCL1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.677E-06 | 2.387E-04 | ABL1, ATM, MAPT, MCL1, PARP1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.951E-06 | 2.706E-04 | AKR1B1, AKR1B10, ALDH1A1, AOX1, XDH |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 2.002E-06 | 2.742E-04 | ALOX15, ALOX5, HPGD |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.667E-06 | 4.669E-04 | ATM, CASP1, CYP1A1, HIF1A, HSD11B2, LMNA, P4HB, PTK2B, TP53 |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 5.306E-06 | 6.419E-04 | ABCC1, ABCG2, ATM, HTT, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0032501; multicellular organismal process | GO:0060020; Bergmann glial cell differentiation | 5.569E-06 | 6.626E-04 | ABL1, MAPK1, PTPN11 |
| BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 5.569E-06 | 6.626E-04 | HIF1A, MCL1, PARP1 |
| MF | GO:0005488; binding | GO:0051287; NAD binding | 8.507E-06 | 9.262E-04 | ALDH1A1, AOX1, HPGD, HSD11B2, PARP1 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.316E-05 | 1.308E-03 | ABCC1, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.392E-05 | 1.365E-03 | ABCG2, ABL1, CA2, CA7, ESR1, HIF1A, HTT, MAPK1, NMUR2, PLA2G1B, PTK2B, TP53 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.418E-05 | 1.378E-03 | ABL1, AKR1B1, ALOX5, APEX1, ATM, BLM, BRCA1, CASP7, CDC25B, ESR1, ESR2, ESRRA, ESRRB, HIF1A, HPGD, HTT, KMT2A, LMNA, MAPK1, MCL1, NFKB1, NR1H4, PARP1, POLB, PTPN11, PTPN2, SMN1, SMN2, TNKS, TP53, USP2 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 1.593E-05 | 1.528E-03 | APEX1, BLM, BRCA1, POLB, TP53 |
| BP | GO:0065007; biological regulation | GO:0032147; activation of protein kinase activity | 1.723E-05 | 1.624E-03 | ABL1, ADRA2A, ADRA2C, EGFR, MAPK1, PLA2G1B, PTK2B, PTPN1, PTPN11 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.918E-05 | 1.778E-03 | ATM, MAPK1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 2.195E-05 | 1.945E-03 | AOX1, XDH |
| BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 2.195E-05 | 1.945E-03 | EGFR, NMUR2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.195E-05 | 1.945E-03 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.195E-05 | 1.945E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.771E-05 | 2.375E-03 | ABL1, ATM, CASP1, CASP7, CYP1B1, HPGD, HTT, MAPT, MCL1, PTPN2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.455E-05 | 2.849E-03 | BRCA1, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 3.496E-05 | 2.873E-03 | ADRA2A, EGFR, MAPK1, PDE5A, PLA2G1B, PTK2B, PTPN1, PTPN11 |
| BP | GO:0032502; developmental process | GO:0048538; thymus development | 4.943E-05 | 3.928E-03 | ABL1, ATM, MAPK1, TYR |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 5.065E-05 | 3.981E-03 | ABL1, ACHE, AKR1B1, APEX1, CA4, EGFR, HTT, NPC1, PTK2B, TNKS2, TYR, USP2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.418E-05 | 4.199E-03 | ALOX15, ALOX5, HPGD |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.715E-05 | 4.351E-03 | ABL1, CA2, CA7, HTT, PARP1, PLA2G1B, PTK2B |
| MF | GO:0003824; catalytic activity | GO:0042578; phosphoric ester hydrolase activity | 5.698E-05 | 4.351E-03 | ALPI, APEX1, CA3, CDC25B, PDE5A, PTPN1, PTPN11, PTPN2, TDP1 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 5.853E-05 | 4.426E-03 | BRCA1, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 6.124E-05 | 4.555E-03 | ABL1, APEX1, CDC25B, CYP1A1, PTPN11, USP2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.557E-05 | 4.672E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.565E-05 | 4.672E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 6.565E-05 | 4.672E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 6.565E-05 | 4.672E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.565E-05 | 4.672E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.565E-05 | 4.672E-03 | GPBAR1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0051882; mitochondrial depolarization | 6.565E-05 | 4.672E-03 | ABL1, CASP1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.565E-05 | 4.672E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.565E-05 | 4.672E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 6.565E-05 | 4.672E-03 | GAA, MGAM |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.565E-05 | 4.672E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0051972; regulation of telomerase activity | 8.305E-05 | 5.704E-03 | ATM, MAPK1, TNKS, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 8.258E-05 | 5.704E-03 | ABL1, AKR1B1, AKR1B10, ALDH1A1, ALOX15, ALOX5, AOX1, BLM, CA1, CA2, CA3, CA7, CASP1, CASP7, CDC25B, HBB, HIF1A, HPGD, HSD17B1, HTT, KMT2A, LMNA, MAPK1, MAPT, MCL1, NFKB1, PDE5A, PLA2G1B, PTK2B, PTPN1, PTPN11, PTPN2, RAB9A, SMN1, SMN2, TNKS, TNKS2, TP53, TYR, XDH |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 8.703E-05 | 5.904E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AOX1, BLM, HPGD, KMT2A, MAPT, MCL1, NFKB1, TYR, XDH |
| MF | Unclassified; | GO:0032403; protein complex binding | 8.703E-05 | 5.904E-03 | ABL1, ACHE, ADRA2A, APEX1, ATM, EGFR, ESRRB, P4HB, PTK2B, PTPN1, PTPN11, PTPN2, TSHR |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 9.841E-05 | 6.494E-03 | ABL1, APEX1, CA5A, CA5B, CASP1, CYP1A1, CYP1B1, CYP2D6, ESR2, HSD17B10, MAOA, MAPK1, MCL1, NFKB1, PARP1, PTPN11, TP53 |
| BP | GO:0008152; metabolic process | GO:0010506; regulation of autophagy | 1.007E-04 | 6.625E-03 | ABL1, ATM, CASP1, HIF1A, HTT, MAPT, MCL1, NPC1 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 1.088E-04 | 7.115E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:1900542; regulation of purine nucleotide metabolic process | 1.195E-04 | 7.764E-03 | ADRA2A, ESRRB, HIF1A, PARP1, PDE5A, PTK2B, TSHR |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.217E-04 | 7.867E-03 | ATM, PARP1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.227E-04 | 7.902E-03 | ABL1, ACHE, CASP1, EGFR, HIF1A, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.265E-04 | 8.098E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.309E-04 | 8.098E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.309E-04 | 8.098E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.309E-04 | 8.098E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.309E-04 | 8.098E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.309E-04 | 8.098E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 1.307E-04 | 8.098E-03 | APEX1, EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, KMT2A, NFKB1, NR1H4, PARP1, TDP1, TP53 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.309E-04 | 8.098E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 1.309E-04 | 8.098E-03 | GAA, MGAM |
| MF | GO:0005488; binding | GO:0030971; receptor tyrosine kinase binding | 1.404E-04 | 8.563E-03 | PTPN1, PTPN11, PTPN2, TP53 |
| BP | GO:0002376; immune system process | GO:0045637; regulation of myeloid cell differentiation | 1.434E-04 | 8.647E-03 | CA2, ESRRA, HIF1A, KMT2A, PTK2B, PTPN2, THPO |
| BP | GO:0009987; cellular process | GO:0001775; cell activation | 1.563E-04 | 9.276E-03 | ABL1, ADRA2A, ADRA2C, ALOX5, EGFR, GAA, HBB, MAPK1, MAPT, MGAM, NFKB1, PTK2B, PTPN11, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.580E-04 | 9.350E-03 | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.673E-04 | 9.820E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.824E-23 | 1.985E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.050E-18 | 5.717E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.440E-16 | 1.800E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.479E-14 | 3.855E-11 | ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, TBXAS1, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.120E-22 | 2.004E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.136E-10 | 1.911E-08 | HSD11B1; HSD11B2; HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.861E-09 | 2.175E-07 | MGAM; PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; HSD11B1; CYP2C9; AKR1B10; HSD17B1; ALOX5; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; AOX1; ALPI; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.278E-09 | 1.956E-07 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.740E-08 | 9.808E-07 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.077E-08 | 1.216E-06 | HSD11B1; CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.062E-07 | 2.376E-06 | ABCC1; ABL1; CYP1B1; MAPK1; ATM; BRCA1; TP53; EGFR; NFKB1; CDC25B; MCL1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.457E-07 | 4.886E-06 | CASP7; PARP1; LMNA; MAPK1; ATM; TP53; NFKB1; MCL1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.203E-08 | 2.353E-06 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.761E-07 | 6.732E-06 | CYP2C9; PLA2G1B; ALOX5; ALOX15; TBXAS1; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.854E-07 | 1.168E-05 | CYP2C9; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.999E-07 | 8.134E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 8.480E-07 | 1.168E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.013E-06 | 1.295E-05 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.146E-06 | 3.754E-05 | HSD17B1; ALOX5; CYP1A1; CYP1B1; CYP19A1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.054E-05 | 2.163E-04 | ABL1; MAPK1; PTPN11; TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.204E-04 | 2.076E-03 | ABL1; MAPK1; PTPN11; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.307E-04 | 2.573E-03 | MAPK1; PTPN11; TP53; HIF1A; ESR1; EGFR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.330E-04 | 2.085E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.258E-04 | 2.573E-03 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.469E-04 | 2.105E-03 | MAPK1; TP53; HIF1A; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.974E-04 | 3.961E-03 | PLA2G1B; ABL1; MAPK1; PTPN11; EGFR; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.004E-05 | 1.123E-04 | MGAM; AKR1B10; GAA; AKR1B1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 7.775E-04 | 4.799E-03 | THPO; AOX1; PTPN11; PTPN2; MCL1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.290E-04 | 4.660E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.093E-03 | 6.114E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1; CDC25B |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.809E-04 | 2.841E-03 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.086E-03 | 6.114E-03 | MAPK1; ESR1; EGFR; ESR2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.258E-03 | 6.622E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.391E-03 | 7.113E-03 | HPGD; KMT2A; ATM; TP53; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.073E-03 | 9.739E-03 | MAPK1; TP53; ESR1; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.204E-03 | 9.746E-03 | ABCC1; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.196E-03 | 1.291E-02 | MAPK1; TP53; EGFR; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.483E-03 | 1.058E-02 | ABL1; ATM; TP53; CDC25B |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.653E-03 | 1.610E-02 | MAPK1; BRCA1; TP53; EGFR; NFKB1; MCL1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.457E-03 | 1.596E-02 | PTK2B; MAPK1; TP53; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 4.244E-03 | 1.550E-02 | PTK2B; MAPK1; PTPN11; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.714E-03 | 8.522E-03 | MAPK1; TP53; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 8.571E-04 | 5.114E-03 | MAPK1; TP53; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.122E-03 | 9.739E-03 | MAPK1; TP53; EGFR |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 5.367E-04 | 3.695E-03 | MAOA; AOX1; TYR |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.137E-03 | 2.263E-02 | MAPK1; PDE5A; ADRA2C; ADRA2A |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.015E-03 | 9.739E-03 | CASP7; CASP1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.247E-03 | 1.291E-02 | MAPK1; TP53; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.286E-03 | 2.263E-02 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.537E-03 | 2.710E-02 | ABL1; MAPK1; HIF1A; TP53; EGFR; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.166E-03 | 1.550E-02 | MAPK1; TP53; EGFR |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.390E-03 | 1.319E-02 | MAPK1; PTPN11; HIF1A |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.201E-03 | 6.513E-03 | CYP3A4; XDH; CES2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.689E-03 | 1.405E-02 | PTPN11; EGFR; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.232E-03 | 9.746E-03 | CASP1; MAPK1; NFKB1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.504E-04 | 3.225E-03 | POLB; PARP1; APEX1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.247E-03 | 1.291E-02 | ABL1; MAPK1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.433E-02 | 3.718E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.333E-03 | 2.263E-02 | ABL1; MAPK1; EGFR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.296E-03 | 2.475E-02 | PTK2B; MAPK1; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.679E-03 | 1.610E-02 | PTPN1; MAPK1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.102E-02 | 3.081E-02 | MAPK1; HIF1A; EGFR |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.352E-02 | 3.634E-02 | PTPN1; PTPN11; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.103E-03 | 2.263E-02 | CASP1; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.386E-02 | 3.647E-02 | CASP7; MAPK1; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.804E-03 | 2.583E-02 | PARP1; ATM; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.670E-02 | 4.270E-02 | ALOX5; MAPK1; NFKB1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.360E-02 | 3.634E-02 | HSD11B2; MAPK1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.711E-02 | 4.314E-02 | ABCC1; ABCG2 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 6.675E-03 | 2.212E-02 | MAPK1; EGFR |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.675E-03 | 2.329E-02 | MAPK1; TP53 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 9.294E-03 | 2.683E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.167E-02 | 3.213E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.868E-03 | 1.644E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.029E-04 | 2.018E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A; EGFR; EGFR; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; ABL1; HIF1A; MAPK1; EGFR; TP53 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; PTK2B |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; TBXAS1; MGAM; PTPN1; PTPN1; NFKB1; GPBAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; MGAM; PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | MCL1; CDC25B; CA1; CA9; ABL1; ACHE; HIF1A; MAPK1; NFKB1; EGFR; PARP1; TP53; ESR1; ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1; TYR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM; PDE5A |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; PDE5A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; CASP1; TYR |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; PARP1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; PDE5A |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESRRA; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ADRA2C; ADRA2A; ESR1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR; ATM |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; PDE5A; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |